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Brucellosis is a bacterial zoonotic disease affecting several mammalian species that is 
transmitted to humans by direct or indirect contact with infected animals or their products. 
In cattle, brucellosis is almost invariably caused by Brucella abortus. Live, attenuated 
Brucella vaccines are commonly used to prevent illness in cattle, but can cause abortions 
in pregnant animals. It is, therefore, desirable to design an effective and safer vaccine 
against Brucella. We have used specific Brucella antigens that induce immunity and 
protection against B. abortus. A novel recombinant multi-epitope DNA vaccine  specific 
for brucellosis was developed. To design the vaccine construct, we employed bioin-
formatics tools to predict epitopes present in Cu–Zn superoxide dismutase and in the 
open reading frames of the genomic island-3 (BAB1_0260, BAB1_0270, BAB1_0273, 
and BAB1_0278) of Brucella. We successfully designed a multi-epitope DNA plasmid 
vaccine chimera that encodes and expresses 21 epitopes. This DNA vaccine induced 
a specific humoral and cellular immune response in BALB/c mice. It induced a typical 
T-helper 1 response, eliciting production of immunoglobulin G2a and IFN-γ particularly 
associated with the Th1 cell subset of CD4+ T cells. The production of IL-4, an indicator 
of Th2 activation, was not detected in splenocytes. Therefore, it is reasonable to suggest 
that the vaccine induced a predominantly Th1 response. The vaccine induced a statis-
tically significant level of protection in BALB/c mice when challenged with B. abortus 
2308. This is the first use of an in silico strategy to a design a multi-epitope DNA vaccine 
against B. abortus.
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inTrODUcTiOn
Brucellosis, caused by facultative Gram-negative intracellular coccobacilli grouped in the genus 
Brucella (1), is a zoonotic disease with a high incidence and prevalence worldwide. Brucellosis 
affects mammals, and it can considerably undermine the health and productivity of domestic 
livestock. The most frequent clinical symptom in livestock after Brucella infection is abortion 
(2). In humans, the disease has a wide spectrum of clinical manifestations. They range from 
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simple fever to major complications in which function in 
the nervous, digestive, genital-urinary, cardiovascular, and 
muscular systems is compromised, sometimes leading to death 
(3). Brucellosis can impose a significant economic burden on 
animal production (reduction in milk production, abortions, 
delayed in conception). In cattle, it has been estimated that 
more than 300,000 animals, out of the 1.4 billion in the world, 
are infected (4). Brucellosis is one of the most common zoonotic 
diseases in humans, with more than 500,000 cases reported 
annually. However, depending upon the system of controls and 
the socioeconomic conditions, official reports only account for 
a fraction of the true incidence of this disease, and different 
countries have reported from 0.09 to 1603 cases per million 
inhabitants (5).
Infection by Brucella spp. is usually associated to an acute 
inflammatory reaction, the principal mechanism against local 
proliferation of Brucella organisms. Infection initially prompts 
an innate immune response that reduces the number of bacteria 
(6). The innate response activates immunity mediated by cells, 
in which CD4+ and CD8+ T lymphocytes, macrophages (MΦ), 
dendritic cells (DCs), and pro-inflammatory cytokines, such 
as interferon-gamma (IFN-γ) and tumor necrosis factor-alpha 
(TNF-α), participate to confer protection (7). Although the 
host raises strong immune response, Brucella abortus has the 
capacity to survive inside MΦ and DCs, expressing a number of 
virulence factors that allow it to reach its replicative niche and to 
avoid immune-mediated destruction (8). It has been shown that 
antigen O protects Brucella from intracellular death mechanisms, 
while lipid A is involved in evasion of the innate immune system 
during the first stages of infection (9). Some additional virulence 
factors have been reported to be involved in intracellular replica-
tion and immune evasion. These include VirB type IV secretion 
(10), BTP1, a seven-helix transmembrane protein that prevents 
maturation of DCs (11), a BvrR/BvrS regulatory system of two 
components (12), and the RNA chaperone protein Hfq (13). 
B. abortus contains a Cu–Zn superoxide dismutase (SOD1), an 
homodimeric metalloenzyme (14). SOD1 catalyzes the dismuta-
tion of the superoxide anion O2
−  to O2 and H2O2, detoxifying 
superoxide radicals generated during the host antimicrobial 
immune response (15). It has been observed that a DNA vaccine 
with the gene sequence for this protein (sodC) is highly immu-
nogenic (16, 17).
One characteristic of Brucella is a limited genetic diversity. This 
is manifested by the small number of differences responsible for 
host preferences and by virulence restrictions (18). The Brucella 
genome incorporates transfer-acquired mobile elements referred 
to as genomic islands (GIs). Nine GIs have been identified in 
Brucella (19). GI-3 is present in B. abortus, Brucella melitenses, 
and Brucella ovis. This GI contains 25 genes, many of which 
have unknown function, and several pseudogenes (20). GI-3 in 
B. abortus 2308 includes open reading frame (ORF) BAB1_0260, 
BAB1_0270, BAB1_0273, BAB1_0278, and BAB1_0278a. 
Our group has reported that BAB1_0270, described as a zinc-
dependent metallopeptidase protein, and BAB1_0278, which has 
homology with the GcrA superfamily, are involved in Brucella 
virulence. Their deletion affects the capacity of Brucella to invade 
phagocytic cells and to survive within them (21, 22). Furthermore, 
DNA vaccine encoding BAB1_0270 (23), BAB1_0278 (24), and 
BAB1_0278a, a hypothetical ABC-type transporter (25), were 
able to induce an immune response and protection against 
B. abortus 2308 infection. Immunization with the recombinant 
flagellar protein (BAB1_0260) also induced protection (26). 
Based on bioinformatics analysis BAB1_0273, a possible DNA-
binding protein, is a putative antigen.
Despite the existence of effective commercial vaccines against 
brucellosis and a diagnostic test, it has not been possible to eradi-
cate the disease. The main vaccines currently used for cattle are 
based on live bacteria attenuated to decrease their pathogenicity. 
Cattle are often vaccinated with B. abortus S19 or RB51, which, 
although providing good protection, may induce abortion if 
administered to gravid females (27), and are potentially infec-
tious to humans (28). Recent advances in genomics, proteomics, 
recombinant DNA techniques, and vaccinology have made 
possible the development of safer vaccines, which overcome the 
drawbacks associated with live-attenuated vaccines. For example, 
DNA vaccines offer the possibility of inducing both humoral 
and cellular immune responses, and potentially can prolong the 
expression of an antigen (29). The use of epitopes in the design 
of this type of vaccine is a new alternative in the development 
of multi-epitope DNA vaccines (30–32). In this strategy, an 
informed selection of antigenic determinants that correlate with 
immunogenicity was used.
In this study, we have predicted antigenic determinants 
using bioinformatics tools from any ORF codified in GI-3 
from B. abortus and designed a multi-epitope chimeric DNA 
vaccine. Humoral, cell-mediated, and protective immunity 
induced by this multi-epitope DNA vaccine was examined in 
BALB/c mice.
MaTerials anD MeThODs
animals
Seven- to eight-week-old female isogenic BALB/c mice (obtained 
from the Instituto de Salud Pública, Santiago, Chile) were ran-
domly allocated to three groups. Mice were kept in conventional 
animal facilities and received water and food ad  libitum. All 
animals were handled in accordance with the regulations of 
the Bioethics Committee of the Faculty of Biological Sciences, 
Universidad de Concepción regulations. The Bioethics and 
Safety committee of the Faculty of Biological Sciences of the 
Universidad de Concepción approved this study. All efforts were 
made to minimize animal suffering.
Bacterial strains
Escherichia coli strain BL21 (DE3) pLys (Novagen, Madison, WI, 
USA) was used as the host strain for expression of recombinant 
multi-epitope protein and E. coli DH5α (Invitrogen, San Diego, 
CA, USA) was used for obtaining plasmids. Both strains were 
grown at 37°C in LB broth. The virulent B. abortus 2308 and 
the attenuated strain RB51 were obtained from our culture col-
lection. Bacterial cells were grown under aerobic conditions in 
Trypticase soy broth (Difco Laboratories, Detriot, MI, USA) for 
72 h at 37°C.
TaBle 1 | Brucella abortus proteins used to design the multi-epitope Dna vaccine.
Protein name locus tag Position genebank iD length (aa)
Copper/Zinc superoxide dismutase BAB2_0535 AM040265.1:534069–534590 CAJ12701.1 173
Flagellar protein FlgJ BAB1_0260 AM040264.1:263739–265859 CAJ10216.1 706
Zinc-dependent metallopeptidase BAB1_0270 AM040264.1:270965–271513 CAJ10226.1 182
Hypothetical DNA-binding protein BAB1_0273 AM040264.1:272920–273165 CAJ10229.1 81
Hypothetical GcrA protein BAB1_0278 AM040264.1:275602–275838 CAJ10234.1 78
Hypothetical ABC-type transporter BAB1_0278a AM040264.1:275322–275654 EEP63779.1 110
FigUre 1 | Verification of pV-MeB Dna vaccine and pQe80l-MeB plasmids. (a) Restriction analysis of pV-MEB plasmid digested with BamHI and PstI  
(line 1) (B) Restriction analysis of pQE80L-MEB plasmid digested with BamHI and PstI (line 1). LM, DNA size marker (1 kb DNA ladder).
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epitope Prediction
The selected protein sequences (Table 1) were obtained from the 
NCBI Database. To find promising epitopes, we used the Immune 
Epitope Database (33). This database contains epitope informa-
tion from 99% of all papers published about immune epitopes 
(33). We used the T Cell Epitope Prediction Tools to find peptides 
binding to MHC class I and class II molecules. Epitope predic-
tion was performed for H2-Dd, H2-Kd, H2-Ld alleles and H2-IEd, 
H2-IAd alleles, and MHC-I and MHC-II haplotypes in BALB/c 
mice. We used a consensus method consisting of a combination 
of the Stabilized Matrix Method (34), Artificial Neural Network 
(35), and Scoring Matrices derived from Combinatorial Peptide 
Libraries (36). We set a threshold <20 of percentile rank and 
selected all peptides lower than this.
construction of recombinant Plasmids
pVAX1 vector (Thermo Fisher Scientific Inc., MA, USA), 
designed for use in the development of DNA vaccines, and 
pQE80L bacterial laclq vector (Qiagen), for expressing 
N-terminally 6xHis-tagged proteins, were used to induce the 
expression of recombinant protein. The multi-epitope genes were 
chemically synthesized by GenScript, Inc. (Piscataway, NJ, USA), 
with codon optimization for mouse and E. coli. The Kozak or 
Shine-Dalgarno sequence was included in the respective genes. 
The genes were inserted into pUC57 to generate two expression 
vectors: pUC57-MEBe (expressing to the recombinant protein) 
and pUC57-MEBm (used to construct the DNA vaccine). Both 
constructs were digested with BamHI-PstI and subcloned into 
BamHI-PstI-digested pVAX1 or BamHI-PstI-digested pQE80L. 
We obtained pV-MEB (multi-epitope DNA vaccine for Brucella) 
and pQE80L-MEB plasmids and confirmed them by restriction 
digestion analysis (Figure 1). We observed 1140 base pairs (bp) 
corresponding to MEBm fragment (A) and 1098 bp correspond-
ing to MEBe fragment (B), respectively.
immunization
BALB/c mice were randomly divided into three groups consisting 
of 10 mice per group. Group 1 was injected with 100 µg of the pV-
MEB vaccine in 100 µl of phosphate buffer saline (PBS), divided 
into two injections of 50 µl, in each posterior tibialis muscle. As 
negative controls, groups of mice received either 100 µg pVAX1 
in 100 µl of PBS or 100 µl of PBS, injected as described above for 
the experimental group (23). All groups were immunized three 
times at 15-day intervals.
Purification of recombinant  
Multi-epitope Protein
To obtain the multi-epitope recombinant protein, E. coli BL-21 
were chemically transformed with pQE80L-MEBe, and we 
standardized the protocols to carry out the purification of 
the rMEB protein. Transformed bacteria were grown in LB 
broth at 37°C to mid-log phase [optical density at 600  nm 
(OD600), 0.6–0.8]. To induce the expression of recombinant 
protein, bacteria were cultured with 0.5  mM Isopropyl β-d-
1-thiogalactopyranoside (IPTG) for 4 h at 27°C to induce the 
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expression of recombinant protein. Thereafter, the transformed 
bacterial cells were collected by centrifugation and then 
disrupted by sonication in Tris–HCl buffer plus 0.2  mM of 
phenylmethylsulfonyl fluoride (PMSF). This preparation was 
centrifuged at 12,000  g for 20  min, the soluble fraction was 
saved and the insoluble fraction was denatured with Denaturing 
Binding Buffer (0.2 mM PMSF; 20 mM Tris–HCl pH 8; 0.5 M 
NaCl; 6  M Urea; 10  mM Imidazole). The his-tagged rMEB 
protein was purified by Ni2+-chelated affinity chromatography 
with HisTrap FF crude columns (GE Healthcare Life Sciences), 
according to the manufacturer’s instructions. The elution was 
performed with 100 mM of Imidazole. The eluate was concen-
trated and desalinated using a filter with a molecular weight 
exclusion of 10 kDa (Amicon ultra 100 K, Millipore, MA, USA). 
Protein concentration was determined by the Pierce™ BCA 
Protein Assay kit (Thermo Fisher Scientific Inc.). Recombinant 
multi-epitope proteins were stored at −20°C for later use as 
antigens in a indirect enzyme-linked immunosorbent assay 
(ELISA) and lymphocyte proliferation assays.
humoral immune response
The antibody isotype IgG, IgG1, and immunoglobulin G2a 
(IgG2a) titers were measured from peripheral blood using an 
ELISA. Serum was collected 2 days before each immunization 
and 15 days after the last immunization. Ninety-six-well polysty-
rene microtiter plates (Thermo Fisher Scientific Inc., MA, USA) 
were coated with 1 µg/ml of rMEB or 10 µg/ml of crude Brucella 
protein (CBP) (37), diluted in 0.05  M carbonate–bicarbonate 
buffer (pH 9.6). After overnight incubation at 4°C, the plates were 
blocked with 0.8% gelatin in Tris-buffered saline for 1 h at 37°C. 
Serial twofold dilutions of sera containing primary antibodies 
from test and control animals were added and incubated for 3 h 
at room temperature. Isotype-specific horseradish peroxidase-
conjugated anti-mouse IgG (US Biological, Life Sciences) was 
added at 1:1000 dilution. After 30  min of incubation at room 
temperature, 200 µl of substrate solution (Sigma-Aldrich, Inc.) 
was added to each well. Results were read using a VictorX3 
Multilabel Plate Reader (PerkinElmer, USA) at 450  nm. All 
assays were done in triplicate.
culture of splenocytes and  
lymphocyte Proliferation
Four weeks after the last immunization, mice were euthanized 
and their spleens removed under aseptic conditions. The sple-
nocytes were cultured, at a concentration of 4 × 106 viable cells/
ml (100 µl per well), at 37°C under 5% CO2 in a 96-well flat-
bottom plate (Nunc, Denmark), previously sensitized with 2 µg/
ml or 10 µg/ml of recombinant proteins (rMEB), or 2 µg/ml or 
10 µg/ml CBP. Splenocytes were cultured in RPMI 1640 medium 
(Thermo Fisher Scientific, MA, USA) supplemented with 10% 
heat-inactivated fetal calf serum (GIBCO BRL), penicillin–
streptomycin (50 UI of penicillin; 50 µg/ml streptomycin), and 
amphotericin B (0.25 µg/ml). After 72 h, cells were pulsed for 
8 h with 0.4 μCi thymidine (50 μCi/mmol; Amersham, UK) per 
well and the radioactivity incorporated in the DNA measured 
using a scintillation counter. Concanavalin A (ConA) (Sigma 
Aldrich, MO, USA), at a concentration of 10 µg/ml was used as 
proliferative positive control and 10 µg/ml albumin protein or 
10 µg/ml total E. coli protein (CEP) were used as proliferative 
negative control. Cell proliferation data were expressed as the 
stimulation index of triplicate cultures from a cell pool from 
each group. These were obtained by dividing the amount of 
3H-Thymidine incorporated (c.p.m.) in antigen-stimulated cell 
cultured by the c.p.m. obtained from cells cultured without 
antigen (38).
cytokine elisas
The levels of IFN-γ and IL-4 secreted were measured by antigen-
capture ELISA. Briefly, spleens were aseptically removed from 
experimental and control mice, disaggregated to single cells, 
re-suspended in Red Blood Cell buffer (Promega, Madison, WI, 
USA) to eliminate erythrocytes, and washed three times using 
incomplete RPMI 1640 (Thermo Fisher Scientific, MA). Cells 
were adjusted to a concentration of 4 × 106 viable cells per ml 
in RPMI 1640 supplemented with 10% fetal calf serum (Thermo 
Fisher Scientific, MA, USA) and antibiotic/antimycotic solution 
(100  UI penicillin, 100  µg/ml streptomycin, and 0.25  µg/ml 
amphotericin B). Spleen cell suspensions were cultured in 24-well 
plates (Nunc, Denmark) and stimulated with the recombinant 
multi-epitope B. abortus protein (rMEB) at 2 or 10 µg/ml CBPs 
or medium alone. They were incubated for 48 h at 37°C under 
5% CO2 to induce, in  vitro, the expression of cytokines. After 
centrifugation at 400 × g for 10 min, supernatants were collected 
and cytokines quantified by ELISA sandwich using the Mouse 
IFN-γ and IL-4 ELISA kits (eBiosciences, San Diego, CA, USA), 
following the manufacturer’s instructions. All assays were per-
formed in triplicate.
Protection experiment
The protection experiments were performed as previously 
described (16). Briefly, 4 weeks after last vaccination, four mice 
from each group were challenged by intraperitoneal injection of 
104 CFU B. abortus 2308 per animal. Two weeks later, infected 
mice were euthanized and their spleens were homogenized in 
PBS, with the homogenate serially diluted and cultured in Petri 
dishes containing agar Columbia supplemented with 5% sheep 
blood (bioMériex, Santiago, Chile) for 72  h at 37°C. Bacterial 
counts were recorded and the number of CFU per spleen calcu-
lated. This experiment was repeated twice. When the immuniza-
tions were initiated, one reference-vaccinated control group was 
immunized with 1 × 108 CFU B. abortus RB51 per mouse. Results 
are reported as units of protection represented by the difference 
between mean ±  SD of log10 CFU/spleen of the PBS control 
groups with respect to mean ± SD of log10 CFU/spleen values of 
experimental groups.
statistical analysis
The immune response in mice was analyzed using a two-way 
analysis of variance (ANOVA) and the protective response was 
analyzed using a one-way ANOVA. Data were analyzed using 
Prism 5.0 (GraphPad software). Differences were considered 
significant if P < 0.05.
TaBle 2 | epitope prediction by computer modeling.
allele Pi Pf Peptide Peptide selected
Cu–Zn SOD MHC-I H-2-Ld 60 68 TPGYHGFHV TPGYHGFHV
H-2-Kd 92 102 HYDPGNTHHHL HYDPGNTHHHL
MHC-II H2-IAd 6 20 IASTMVLMAFPAFAE FIASTMVLMAFPAFAE
H2-IAd 5 19 FIASTMVLMAFPAFA
H2-IAd 7 21 ASTMVLMAFPAFAES
BAB1_0260 MHC-I H-2-Kd 199 207 NYARSVGAI NYARSVGAI
H-2-Kd 311 322 SYAAPRQGGVNI SYAAPRQGGVNI
H-2-Ld 114 122 APGNNFFGI APGNNFFGI
H-2-Ld 155 166 SPQDSVAGYADF SPQDSVAGYADF
MHC-II H2-IAd 353 367 NDPMRALQAQKLQLE NDPMRALQAQKLQLEM
BAB1_0270 MHC-I H-2-Ld 35 43 FPVMDFLEL FPVMDFLEL
H-2-Ld 128 138 EPQANQFAGEL EPQANQFAGEL
MHC-II H2-IAd 46 60 CQRMGMVDLRIKTQQ LCQRMGMVDLRIKTQQ
H2-IAd 45 59 LCQRMGMVDLRIKTQ
H2-IAd 155 169 MQRHSVSRGAADIRL VMQRHSVSRGAADIRL
H2-IAd 154 168 VMQRHSVSRGAADIR
H2-IAd 153 167 DVMQRHSVSRGAADI
BAB1_0273 MHC-I H-2-Kd 35 43 RYEGGSGVL RYEGGSGVL
H-2-Kd 48 60 QYIEALIAVLTAA QYIEALIAVLTAA
H-2-Kd 48 56 QYIEALIAV
MHC-II H2-IAd 3 17 ITAEQLRAARALLKM ITAEQLRAARALLKM
H2-IAd 9 23 RAARALLKMEQRALA RAARALLKMEQRALA
BAB1_0278 MHC-I H-2-Ld 7 16 SPLSEALPMF SPLSEALPMF
H-2-Ld 7 15 SPLSEALPM
H-2-Ld 21 28 SPHEGFRL SPHEGFRLADL
H-2-Ld 21 31 SPHEGFRLADL
BAB1_0278a MHC-I H-2-Ld 22 32 FPANKKNGYAL FPANKKNGYAL
MHC-II H2-IAd 44 58 SAPASIQEADDFLLA SAPASIQEADDFLLA
Pi Pf Peptide reference
Cu–Zn SOD – – 75 86 GGAPGEKDGKIVPAG Tabatabai and Pugh (39)
Pi, initial position of peptides in each protein; Pf, final position of peptides in each protein.
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resUlTs
epitope Prediction
Using the Immune Epitope Database (IEDB, www.iedb.org), 
we identified epitopes suitable for constructing a multi-epitope 
DNA chimeric vaccine against B. abortus. The epitopes identified 
(Table 1) are specific for MHC class I and MHC class II molecules. 
However, while all sequences had putative epitopes for MHC 
class I and class II molecules, the BAB1_0278 ORF only showed 
epitopes for MHC class I (Table 2). Peptides were selected based 
on having a lower percentile rank score. Non-redundant peptides 
were selected to construct the DNA vaccine. An immunodomi-
nant peptide of the Cu, Zn superoxide dismutase protein from 
B. abortus, described previously in the literature (39), was also 
included in the vaccine sequence. Finally, 21 epitopes were used 
to construct the DNA vaccine. To connect the epitopes, we used 
a GDGDG linker sequence, a rationally designed sequences used 
to link multi-epitope vaccines (40). The final design of the multi-
epitope vaccine is shown in Figure 2A.
Production of recombinant Multi-epitope 
Protein of Brucella
To construct the recombinant protein, E. coli BL21 (DE3) cells 
were transformed with the pQE80L-MEB plasmid and expres-
sion of the 6xHis-Tagged protein was induced. The recombinant 
protein was mainly expressed in the soluble fraction of the 
transformed bacteria after their sonication (Figure 2B, lane 4). 
The recombinant protein of B. abortus (rMEB) was induced and 
detected by Western blot. Its weight was ~37 kDa, the expected 
mass (Figure 2C).
humoral immune response  
of immunized Mice
Specific antibodies for rMEB and CBPs were measured in order to 
evaluate the humoral immune response. We performed ELISAs 
to detect specific IgG, IgG1, and IgG2a antibodies induced in 
mice against rMEB and CBP. Serum from mice immunized with 
multi-epitope DNA vaccine for Brucella (pV-MEB) contained 
FigUre 2 | MeB Dna vaccine design and identification of rMeB protein. (a) Multi-epitope vaccine sequence spaced by GDGDG linker sequence. (B) 
SDS-PAGE analysis of rMEB. Lane 1, marker; lane 2, total proteins obtained from insoluble extract from Escherichia coli transformed with pQE80L-MEBe plasmid; 
lane 3, eluent from Ni2+-chelated affinity chromatography of the insoluble extract from E. coli; lane 4, total proteins obtained from the soluble extract from E. coli 
transformed with pQE80L-MEBe plasmid; lane 5, eluent from Ni2+-chelated affinity chromatography of the soluble extract from E. coli. (c) Western blot analysis of 
rMEB with anti-His-tag monoclonal antibody.
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significant titers of IgG specific for rMEB at 30 days after the first 
immunization. IgG titers were higher at 45  days, compared to 
the negative-control groups pVAX and PBS (Figure  3A). The 
same pattern was observed for IgG against CBPs (Figure 3B). No 
rMEB- or CBP-specific IgG1 was detected in serum from mice 
immunized with pV-MEB (Figures 3C,D). Titers of IgG2a anti-
bodies specific for rMEB proteins significantly differed between 
the pV-MEB groups immunized (P < 0.05) only after the second 
immunization between pV-MEB groups immunized, compared 
to PBS and pVAX controls (Figure  3E). On the other hand, a 
significant titer of IgG2a specific for CBP was observed after the 
third immunization with pV-MEB, compared to PBS and pVAX 
negative controls (Figure 3F).
cellular immune response
To evaluate the cellular immune response, splenocytes were 
obtained from mice immunized with pV-MEB, p-VAX, or PBS 
at 30 days after the last immunization. In vitro stimulation using 
splenocytes from pV-MEB mice immunized with 10 or 2  µg/
ml rMEB protein resulted in a significant increase in cell prolif-
eration in relation to the control group (P < 0.001 and P < 0.05, 
respectively; Figure 4A). In vitro stimulation using splenocytes 
from pV-MEB mice immunized with 10 and 2  µg/ml of CBP 
also induced a significant increase in splenocytes proliferation 
(P < 0.001 and P < 0.01, respectively; Figure 4B). In this assay, 
10  µg/ml of ConA was used as lymphoproliferation control. It 
induced a strong lymphoproliferative response in all experimen-
tal groups (data not shown). In vitro stimulation of splenocytes 
with 10 µg/ml crude E. coli protein and 10 µg/ml albumin did 
not induce proliferation across the different experimental groups 
(Figure 4C).
IFN-γ levels in supernatants from cultures of splenocytes 
obtained from the pV-MEB immunization group re-stimulated 
with rMEB or CBP were significantly higher than those in the 
negative-control groups (P <  0.001, respectively) (Figure  5A). 
There were no significant difference in levels of IL-4 secretion 
between the experimental and control groups (Figure 5B).
Protection against Virulent B. abortus 
challenged
The protective capacity provided by the pV-MEB DNA vaccine 
was evaluated 6 weeks after the last immunization. Immunized 
mice were challenged with 104 CFU B. abortus 2308, and after 
2 weeks their spleens were removed, homogenized, and cultured. 
The results showed that pV-MEB DNA vaccine confers protec-
tion against B. abortus 2308. The DNA vaccine induced 1.14 log10 
units of protection (P > 0.005; Figure 6) compared to the PBS 
control group. By comparison, vaccination with live B. abortus 
strain RB51 induced 2.85-log units of protection.
DiscUssiOn
Brucellosis is a worldwide zoonotic disease of increasing inci-
dence. Vaccination of livestock is considered the best prevention 
method, but it is necessary to generate safer and more effective 
vaccine formulations (41). The availability of bioinformatics tools 
and databases allow the design of vaccines without the need for 
in  vitro manipulation of a pathogenic microorganism. Using 
“reverse vaccinology” approach, in  silico genomic databases are 
screened to identify antigenic sequences for new vaccines (42). 
This allows the identification of antigens that would be difficult 
FigUre 3 | Titers of specific igg (a,B), igg1 (c,D), and immunoglobulin g2a (e,F) production after immunization with recombinant pV-MeB vaccine. 
Sera obtained from each group of mice were used for detection of antibodies against purified rMEB proteins (a,c,D) and crude Brucella proteins (B,D,F) by indirect 
enzyme-linked immunosorbent assay. Sera obtained at days 0, 15, 30, and 45 post-immunization were serially diluted in phosphate buffer saline and used in the 
assay (*P < 0.05, **P < 0.01, and ***P < 0.001).
FigUre 4 | lymphocyte proliferation assay after in vitro stimulation with (a) 10 or 2 µg/ml recombinant protein, (B) 10 or 2 µg/ml Brucella abortus 
total proteins (cBP), and (c) 10 µg/ml of crude Escherichia coli proteins and 10 µg/ml of albumin as control. Results are shown as mean ± SD of the 
stimulation index of 3H-thymidine, incorporated from mouse splenocytes (n = 5) (*P < 0.05, **P < 0.01, and ***P < 0.001).
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FigUre 6 | Protection conferred to BalB/c mice immunized with 
pV-MeB vaccine against Brucella abortus 2308. Results are shown as 
mean ± SD of the log10 CFU of B. abortus 2308 per spleen (n = 4), 
**P < 0.01 and ***P < 0.001. aUnits of protection represent the difference 
between log10 CFU values of the phosphate buffer saline group and the log10 
CFU values of the immunized group.
FigUre 5 | Determination of iFn-γ (a) or il-4 (B) production. Splenocytes from pV-MEB pVAX or phosphate buffer saline (PBS) groups were obtained 30 days 
after the last immunization, and were re-stimulated in vitro with 2 µg/ml of recombinant MEB proteins or 10 µg/ml of crude Brucella proteins. Each bar represents the 
geometric mean ± SD (error bars) of the response in spleen cells from individual mice. ***P < 0.001, statistically significant difference compared to the PBS group.
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using traditional methods (42). It has been observed that recom-
binant protein vaccines induce a humoral/Th2 immune response 
and it is suggested that a boost with a protein improve the protec-
tive efficacy of the antibodies (43). The effect of DNA vaccines, 
however, is based toward a Th1 response (44–46).
DNA vaccine have a number of advantages, including ease 
storage, flexibility of antigen codification, and the presence of 
CpG motifs, which improve the immune response (45). Mono-
antigenic DNA vaccines induce a good immune response, but 
tend to induce less protection against pathogens compared to 
poly-antigenic vaccine (47, 48). In the case of B. abortus, the 
three antigens: BCSP31, Cu–Zn SOD, and L7/L12 ribosomal 
proteins, when giving together as part of a formulation, improve 
the immune response against pathogenic B. abortus (49).
Within the last few years, the use of epitopes in vaccines has 
become a valid alternative for improving the efficacy of tradi-
tional vaccine, based on a “natural” form of the pathogen (50). 
Multi-epitope peptide DNA vaccines are effective against some 
viruses (30, 51, 52) and they are potentially effective against some 
bacteria such as Helicobacter pylori (53) and in cancer prevention 
(54, 55).
Multi-epitope DNA vaccines more faithfully mimic antigen 
processing and presentation during natural infection (30). In 
addition, multi-epitope DNA vaccines induce more potent 
immunoreaction than whole protein vaccine (30). Since the 
epitopes are derived from multiple antigens and packaged into 
a relatively small delivery vehicle, the vaccine can induce power-
ful cross-reactive responses toward multiple antigens and elicit 
a strong humoral and cellular immune response (56). In this 
study, we used bioinformatics methods to identify epitopes on 
antigenic proteins of B. abortus and to design a multi-epitope 
chimeric DNA vaccine. We performed the epitope prediction 
using bioinformatics resources available online, including 
NetChop, SYFPEITHI, or BIMAS. However, these database 
had a 50% prediction assertiveness about the prediction (57). 
The predictive power of the IEDB has been expanded with the 
provision of a large number of published epitopes and full-scale 
MHC-binding peptides (58), so we opted to use the IEDB server. 
In order to design a rational vaccine against Brucella, we focused 
on finding MHC class I or MHC class II binding peptides known 
to orchestrate primarily a T-cell immune response, since B. 
abortus is known as a facultative intracellular pathogen (59). We 
selected 21 dominant epitopes from ORFs present within GI-3 
and proteins described as antigens of immunological interest 
(Table 1). Peptides were selected based on their low percentile 
score using observed redundant sequences as a further selection 
criterion, choosing peptides with non-redundant sequences 
(Table  2). For the theoretical binding of peptides we used the 
“GDGDG” sequence as spacer (Figure 2A) (40). The introduc-
tion of GDGDG spacers does not preclude the possibility that 
such linear arrangements of epitopes might contain other cryptic 
epitopes. The presence of this spacer at 15–20 residue intervals 
might help create some secondary and possibly tertiary structure, 
thereby facilitating antigen expression (40). Then, we constructed 
the B. abortus multi-epitope chimeric DNA vaccine using of 
chemical gene synthesis (pV-MEB).
We, next, proceeded to evaluate the immunogenicity and 
protective efficacy conferred by immunization with the multi-
epitope vaccine, peptides present in Cu–Zn superoxide dismutase 
and the ORFs present within GI-3 (BAB1_0260, BAB1_0270, 
BAB1_0273, and BAB1_0278) of B. abortus (16, 21–26). The 
results showed that immunization with pV-MEB triggers a MEB-
specific humoral and cellular immune response in BALB/c mice. 
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At systemic level pV-MEB promotes the stimulation of MEB-
specific IgG2, indicating an adequate induction of a Th1 response. 
In vitro stimulation of splenocytes from pV-MEB immunized 
mice induced the highest proliferation in response to antigen, 
confirming the in vivo translation of the MEB synthetic gene and 
subsequent induction of a cell-mediated immune response. We 
used albumin and E. coli proteins as control of proliferation and in 
both cases splenocytes did not proliferate. Therefore, the immune 
response inducing by pV-MEB DNA vaccine was specific to MEB 
protein and Brucella antigens. Antigen-stimulated splenocytes 
from vaccinated mice produced IFN-γ. The level of IFN-γ and the 
in vitro proliferation of splenocytes stimulated by MEB recombi-
nant protein demonstrated that pV-MEB DNA vaccine induces 
a strong immunoreaction and a polarized Th1 response against 
Brucella infection, which is associated to effective clearance of 
intracellular pathogens, so essential feature for a Brucella vaccine 
(7, 59). The immunogenicity induced by pV-MEB DNA recombi-
nant plasmid was evaluated by challenging immunized mice with 
B. abortus 2308 strain. Our results confirmed that immunization 
with pV-MEB induced immunogenicity associated with signifi-
cant protection, but protection induced by attenuated B. abortus 
RB51 was more robust.
In conclusion, we have shown that a B. abortus multi-epitope 
chimeric DNA vaccine (pV-MEB) elicits strong humoral and 
cellular protective immunity. Future studies must include an 
array of epitopes or combination of peptides and adjuvants as 
alternatives to conventional vaccine design. This study provides 
a starting point for the development of multi-epitope DNA vac-
cines against B. abortus.
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